Pharma, Biotech and Generics Industry News | The Pharmaletter
2024年11月20日 · The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to the publication of disappointing research results in the sphere, or an ominous stance taken by a major regulator on a key filing, but rather a political development that could spell trouble for the vaccines field as a whole.
Pharmaceutical Industry News | The Pharmaletter
2024年11月12日 · The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to the publication of disappointing research results in the sphere, or an ominous stance taken by a major regulator on a key filing, but rather a political development that could spell trouble for the vaccines field as a whole.
Pharma and Biotech News | The Pharmaletter
2024年11月21日 · Japanese drugmaker Chugai, which is majority owned by Roche, On Friday revealed that Zenyaku Kogyo has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW), for an additional dosage and administration of an anti-CD20 monoclonal antibody Rituxan (rituximab) intravenous injection 100mg and 500mg, which is co-marketed by both companies, for chronic idiopathic ...
Pharmaceutical Generics Industry News | The Pharmaletter
2024年9月9日 · Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets.
FDA drug regulation and approval news | The Pharmaletter
2024年11月13日 · Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) that addresses the supplemental New Drug Application (sNDA) for Ocaliva (obeticholic acid, OCA) seeking full approval for the treatment of indicated patients with primary biliary cholangitis (PBC) – a rare ...
Pharma and Biotech News in Brief | The Pharmaletter
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025.
Pharma and Biotech Insights | The Pharmaletter
2024年11月11日 · Pharma and Biotech News Insights. As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live.
EMA drug regulation and approval news | The Pharmaletter
2024年11月15日 · Significant research news last week saw US biotech Scholar Rock release positive new data for its spinal atrophy (SMA) candidate apitegromab. There was a negative development for Johnson & Johnson, which said that, following a data monitoring committee recommendation, it is discontinuing development or its TAR-200 in bladder cancer.
About The Pharma Letter | The Pharmaletter
3 天之前 · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world ...
Biotech Industry News | The Pharmaletter
2024年11月11日 · Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD …